Skip to main content
Registrieren
Springer Medizin
SUCHE
MENÜ 1 2 3 4
nach oben
Erschienen in: InFo Neurologie + Psychiatrie 1/2022

19.01.2022 | COVID-19 | Zertifizierte Fortbildung Neurologie Zur Zeit gratis

Pandemie

Neurologische Nebenwirkungen der COVID-19-Impfung

verfasst von: Prof. Dr. med. Hans-Christoph Diener, Prof. Dr. med. Peter Berlit, Prof. Dr. med. Christian Gerloff, Prof. Dr. med. Dagny Holle-Lee, Prof. Dr. med. Tobias Kurth, ScD Tobias Kurth, Prof. Dr. med. Jörg B. Schulz

Erschienen in: InFo Neurologie + Psychiatrie | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Auszug

Nach einer Impfung gegen COVID-19 kann es in extrem seltenen Fällen zu neurologischen Komplikationen kommen. Ein ursächlicher Zusammenhang ist belegt zwischen der Anwendung von Vektorimpfstoffen und der Auslösung einer immuninduzierten thrombotischen Thrombozytopenie mit Sinus- und Hirnvenenthrombosen. Weitere mögliche neurologische Komplikationen nach COVID-19-Impfung mit Vektorimpfstoffen sind ischämische Hirninfarkte und Hirnblutungen, das Guillain-Barré-Syndrom, Fazialisparesen und Enzephalomyelitiden. Nach mRNA-Impfstoffen kann es in seltenen Fällen zu einer Myokarditis, einer Perikarditis oder zu Fazialisparesen kommen. …
Literatur
1.
Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE et al. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA 2021 Oct 12;326(14):1390-99
2.
Pottegård A, Lund LC, Karlstad Ø, Dahl J, Andersen M, Hallas J, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ 2021;373:n1114.
3.
Schultz NH, Sorvoll IH, Michelsen AE et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med 2021 Jun 3;384(22):2124-30
4.
See I, Su JR, Lale A, Woo EJ, Guh AY, Shimabukuro TT et al. US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. JAMA 2021;325(24):2448-56
5.
Schulz JB, Berlit P, Diener HC, Gerloff C, Greinacher A, Klein C et al. COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany. Ann Neurol 2021;90(4):627-39
6.
Bikdeli B, Chatterjee S, Arora S et al. Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19. J Am Coll Cardiol 2021;78(4):408-11
7.
Siegler JE, Klein P, Yaghi S et al. Cerebral Vein Thrombosis With Vaccine-Induced Immune Thrombotic Thrombocytopenia. Stroke 2021;52(9):3045-53
8.
Taquet M, Husain M, Geddes JR, Luciano S, Harrison PJ. Cerebral venous thrombosis and portal vein thrombosis: A retrospective cohort study of 537,913 COVID-19 cases. EClinicalMedicine 2021;39:101061
9.
10.
Taquet M, Husain M, Geddes J, Luciano S, Harrison P. COVID-19 and Cerebral Venous Thrombosis: A Retrospective Cohort Study of 513,284 Confirmed COVID-19 Cases. OSF April 26 doi:1017605/OSFIO/H2MT7. 2021.
11.
Ropper AH, Klein JP. Cerebral Venous Thrombosis. New England Journal of Medicine 2021;385(1):59-64
12.
Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A et al. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review. J Neurol Sci 2021;428:117607.
13.
Perry RJ, Tamborska A, Singh B, Craven B, Marigold R, Arthur-Farraj P, et al. Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study. 2021. Lancet 2021;398(10306):1147-56
14.
Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med 2021; 384:2092-101
15.
Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M et al. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. N Engl J Med 2021;384:2202-11
16.
Thiele T, Ulm L, Holtfreter S, Schönborn L, Kuhn SO, Scheer C et al. Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2. 2021 Blood 2021 Jul 29;138(4):299-303
17.
Althaus K, Möller P, Uzun G, Singh A, Beck A, Bettag M, et al. Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia. Haematologica 2021;106(8):2170-79
18.
FACME ad-hoc Expert Working Group. Diagnostic and treatment recommendations from the FACME ad-hoc expert working group on the management of cerebral venous sinus thrombosis associated with COVID-19 vaccination. Neurologia (Engl Ed) 2021;36(6):451-61
19.
20.
Graf T, Thiele T, Klingebiel R et al. Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19- adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis. J Neurol 2021 ;268(12):4483-5
21.
Bourguignon A, Arnold DM, Warkentin TE et al. Adjunct Immune Globulin for Vaccine-Induced Thrombotic Thrombocytopenia. N Engl J Med 2021 Aug 19;385(8):720-8
22.
Patriquin CJ, Laroche V, Selby R et al. Therapeutic Plasma Exchange in Vaccine-Induced Immune Thrombotic Thrombocytopenia. N Engl J Med 2021;385(9):857-9
23.
Rizk JG, Gupta A, Sardar P, Henry BM, Lewin JC, Lippi G et al. Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis: A Review. JAMA Cardiol 2021 Aug 10. doi: 10.1001/jamacardio.2021.3444.
24.
Schulz JB, Berlit P, Diener HC, Gerloff C, Greinacher A, Klein C, et al. COVID-19 vaccine-associated cerebral venous thrombosis in Germany. Ann Neurol 2021 Oct;90(4):627-39
25.
Bjørnstad-Tuveng TH, Rudjord A, Anker P. Fatal cerebral haemorrhage after COVID-19 vaccine. Tidsskr Nor Laegeforen 2021;141.
26.
Kenda J, Lovrič D, Škerget M, Milivojević N. Treatment of ChAdOx1 nCoV-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia Related Acute Ischemic Stroke. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 2021;30(11):106072.
27.
Costentin G, Ozkul-Wermester O, Triquenot A, Cam-Duchez VL, Massy N, Benhamou Y et al. Acute Ischemic Stroke Revealing ChAdOx1 nCoV-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia: Impact on Recanalization Strategy. J Stroke Cerebrovasc Dis 2021 Sep;30(9):105942.
28.
Blauenfeldt RA, Kristensen SR, Ernstsen SL, Kristensen CCH, Simonsen CZ, Hvas AM. Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine. J Thromb Haemost 2021;19(7):1771-5
29.
Bayas A, Menacher M, Christ M, Behrens L, Rank A, Naumann M. Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination. Lancet (London, England) 2021;397(10285):e11-e.
30.
Li X, Ostropolets A, Makadia R, Shoaibi A, Rao G, Sena AG et al. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. BMJ 2021;373:n1435.
31.
Nachamkin I, Shadomy SV, Moran AP et al. Anti-ganglioside antibody induction by swine (A/NJ/1976/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain-Barré syndrome. J Infect Dis 2008;198(2):226-33
32.
Salmon DA, Vellozzi C, Chen RT, Halsey NA. Did the influenza A (H1N1) 2009 monovalent inactivated vaccines increase the risk for Guillain-Barré syndrome? Expert Rev Clin Immunol 2013;9(9):795-7
33.
Luo G, Ambati A, Lin L, Bonvalet M, Partinen M, Ji X et al. Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy. Proc Natl Acad Sci U S A 2018;115(52):E12323-e32.
34.
Petráš M, Lesná IK, Dáňová J, Čelko AM. Is an Increased Risk of Developing Guillain-Barré Syndrome Associated with Seasonal Influenza Vaccination? A Systematic Review and Meta-Analysis. Vaccines (Basel) 2020;8(2):150
35.
Li X, Ostropolets A, Makadia R, Shaoibi A, Rao G, Sena AG, et al. Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study. medRxiv 2021 Apr 17;2021.03.25.21254315.
36.
Berlit P, Lehmann H. Vorsicht vor kausalen Verknüpfungen. DGNeurologie 2021;4(3):149-50
37.
Márquez Loza AM, Holroyd KB, Johnson SA, Pilgrim DM, Amato AA. Guillain- Barré Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial: Temporal Associations Do Not Imply Causality. Neurology 2021 Apr 6;10.1212/WNL.0000000000011881.
38.
Maramattom BV, Krishnan P, Paul R, Padmanabhan S, Cherukudal Vishnu Nampoothiri S, Syed AA et al. Guillain-Barré Syndrome following ChAdOx1-S/nCoV-19 Vaccine. Ann Neurol 2021;90(2):312-4
39.
Allen CM, Ramsamy S, Tarr AW, Tighe PJ, Irving WL, Tanasescu R et al. Guillain-Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination. Ann Neurol 2021;90(2):315-8
40.
Woo EJ, Mba-Jonas A, Dimova RB, Alimchandani M, Zinderman CE, Nair N. Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021. JAMA 2021 Oct 26;326(16):1606-13
41.
Cao L, Ren L. Acute disseminated encephalomyelitis after severe acute respiratory syndrome coronavirus 2 vaccination: a case report. Acta Neurol Belg 2021:1-3
42.
Singh Malhotra H, Gupta P, Prabhu V, Garg RK, Dandu H, Agarwal V. COVID-19 vaccination-associated myelitis. QJM 2021 Mar 31;hcab069
43.
Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397(10269):99-111
44.
Havla J, Schultz Y, Zimmermann H et al. First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine. J Neurol 2021:1-4
45.
Chen S, Fan XR, He S, Zhang JW, Li SJ. Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19. Neurol Sci 2021:1-3
46.
Helmchen C, Buttler GM, Markewitz R, Hummel K, Wiendl H, Boppel T. Acute bilateral optic/chiasm neuritis with longitudinal extensive transverse myelitis in longstanding stable multiple sclerosis following vector-based vaccination against the SARS-CoV-2. J Neurol 2021:1-6
47.
Achiron A, Dolev M, Menascu S, Zohar DN, Dreyer-Alster S, Miron S et al. COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021. Mult Scler 2021;27(6):864-70
48.
Sotoca J, Rodríguez-Álvarez Y. COVID-19-associated acute necrotizing myelitis. Neurol Neuroimmunol Neuroinflamm 2020;7(5):e803
49.
Garjani A, Middleton RM, Hunter R, Tuite-Dalton KA, Coles A, Dobson R et al. COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies. Mult Scler Relat Disord 2021;52:102939.
50.
Ozonoff A, Nanishi E, Levy O. Bell's palsy and SARS-CoV-2 vaccines. Lancet Infect Dis 2021;21(4):450-2
51.
Ozonoff A, Nanishi E, Levy O. Bell's palsy and SARS-CoV-2 vaccines. The Lancet Infectious Diseases 2021;21(4):450-2
52.
Zhou W, Pool V, DeStefano F, Iskander JK, Haber P, Chen RT et al. A potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001. Pharmacoepidemiol Drug Saf 2004;13(8):505-10
53.
Huang WT, Huang WI, Huang YW, Hsu CW, Chuang JH. The reporting completeness of a passive safety surveillance system for pandemic (H1N1) 2009 vaccines: a capture-recapture analysis. Vaccine 2012;30(12):2168-72
54.
Sato K, Mano T, Niimi Y, Toda T, Iwata A, Iwatsubo T. Facial nerve palsy following the administration of COVID-19 mRNA vaccines: analysis of a self-reporting database. Int J Infect Dis 2021;111:310-2
55.
Göbel CH, Heinze A, Karstedt S, Morscheck M, Tashiro L, Cirkel A et al. Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study. Brain Commun 2021;3(3):fcab169.
56.
Sekiguchi K, Watanabe N, Miyazaki N, Ishizuchi K, Iba C, Tagashira Y et al. Incidence of headache after COVID-19 vaccination in patients with history of headache: A cross-sectional study. Cephalalgia 2021:3331024211038654.
57.
Salih F, Schönborn L, Kohler S, Franke C, Möckel M, Dörner T, et al. Vaccine-Induced Thrombocytopenia with Severe Headache. N Engl J Med 2021 Sep 15;NEJMc2112974.
58.
Vogel G, Couzin-Frankel J. Israel reports link between rare cases of heart inflamma-tion and COVID-19 vaccination in young men. Science. 2021;online(01.06.2021).
59.
Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A. Myocarditis and Pericarditis After Vaccination for COVID-19. JAMA 2021 Sep 28;326(12):1210-12
60.
Westbury CF. Bayes' rule for clinicians: an introduction. Front Psychol 2010;1:192.
61.
Kuhnert R, Hecker H, Poethko-Müller C, Schlaud M, Vennemann M, Whitaker HJ, et al. A modified self-controlled case series method to examine association between multidose vaccinations and death. Stat Med 2011;30(6):666-77
Metadaten
Titel
Pandemie
Neurologische Nebenwirkungen der COVID-19-Impfung
verfasst von
Prof. Dr. med. Hans-Christoph Diener
Prof. Dr. med. Peter Berlit
Prof. Dr. med. Christian Gerloff
Prof. Dr. med. Dagny Holle-Lee
Prof. Dr. med. Tobias Kurth, ScD Tobias Kurth
Prof. Dr. med. Jörg B. Schulz
Publikationsdatum
19.01.2022
Verlag
Springer Medizin
Erschienen in
InFo Neurologie + Psychiatrie / Ausgabe 1/2022
Print ISSN: 1437-062X
Elektronische ISSN: 2195-5166
DOI
https://doi.org/10.1007/s15005-021-2149-4

Weitere Artikel der Ausgabe 1/2022

InFo Neurologie + Psychiatrie 1/2022 Zur Ausgabe

Aktuell

Pandemie offenbart Nutzen der EKT-Erhaltungstherapie

Journal club

Erhöhung der Muskelkontraktilität ohne Effekt

Journal club

Nach intrazerebraler Blutung: Antikoagulation erneut starten?

Journal club

Kein Effekt von autologen mesenchymalen Stammzellen bei MS

Journal club

Mobile Stroke Units – auch langfristig besseres Outcome?

Aktuell

SpringerMedizin.de

Corona-Update

Die aktuelle Entwicklung im Überblick: Nachrichten, Webinare, Übersichtsarbeiten.

» zum Update
Bildnachweise